



# Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease

## Citation

Pasterkamp, Gerard, Hester M. den Ruijter, and Peter Libby. 2016. "Temporal Shifts in Clinical Presentation and Underlying Mechanisms of Atherosclerotic Disease." *Nature Reviews Cardiology* 14 (1) (October 20): 21–29. doi:10.1038/nrcardio.2016.166.

## Published Version

10.1038/nrcardio.2016.166

## Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:29694793>

## Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#OAP>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

# **Temporal shifts in clinical presentations and underlying mechanisms of atherosclerotic disease**

**Fractures in the foundation of the concept of vulnerable atherosclerotic plaque.**

**Gerard Pasterkamp <sup>1,2</sup>, Hester M den Ruijter <sup>1</sup>, Peter Libby <sup>3</sup>**

1 Laboratory of Experimental Cardiology, Division Heart and Lungs, University Medical Center Utrecht, the Netherlands.

2 Laboratory of Clinical Chemistry, University Medical Center Utrecht, the Netherlands

3 Cardiovascular Division, Brigham and Womens Hospital and the Harvard Medical School, Boston, Massachusetts, USA.

Address for correspondence

Gerard Pasterkamp

Experimental Cardiology Laboratory

University Medical Center Utrecht

Room G03-648

Heidelberglaan 100

3584CX Utrecht

the Netherlands

[g.pasterkamp@umcutrecht.nl](mailto:g.pasterkamp@umcutrecht.nl)

tel +31 887556051

## **Abstract**

The concept of “the vulnerable plaque” originated from pathological observations in patients who succumbed to fatal acute coronary syndromes. This recognition spawned a generation of research that led to achievement of considerable understanding of how complicated atherosclerotic plaques form and precipitate thrombotic events.

In current practice, an increasing number of patients present with non ST-elevation myocardial infarction (NSTEMI) rather than myocardial infarction (MI) with ST-elevation (STEMI) and survive their first event. The culprit lesions that furnish the pathological substrate for NSTEMI may vary considerably from the so-called “vulnerable plaque.” The shift in clinical presentation of MI and stroke correspond temporally to a progressive change in the characteristics of human plaques away from the supposed characteristics of “vulnerability.” These alterations in the structure and functions of human atherosclerotic lesions may mirror the modifications produced in experimental plaques by lipid lowering, inspired by the “vulnerable plaque” construct.

The shift in the clinical presentations of the acute coronary syndromes mandates a critical reassessment of the underlying mechanisms, proposed risk scores, the results and interpretation of pre-clinical experiments, as well as recognition of the limitations of the use of population data and samples harvested before the application of current preventive interventions.

## **Key points**

- An increasing number of patients presenting with myocardial infarction (MI) are diagnosed with a non ST-elevated myocardial infarction (NSTEMI) rather than a MI with ST-elevation (STEMI) and consequently survive their first event.
- The shift in the clinical presentations of the acute coronary syndromes mandates a critical reassessment of the underlying mechanisms and the concept of the

vulnerable plaque.

- The change in clinical presentation and warrant critical re-assessment of currently applied cardiovascular risk scores, pre-clinical experiments, and the usefulness of population data and samples harvested before the application of current preventive interventions.

## Introduction

### *Temporal changes in the clinical presentation of cardiovascular patients*

Since the 1980s the development and increasingly widespread application of effective pharmacologic lipid-lowering and antihypertensive agents and of percutaneous interventions, along with risk factor management have made inroads curbing the worldwide epidemic of cardiovascular disease. Total age-adjusted cardiovascular death rates have fallen by over 50% in most Western countries. This decline may result in part from improved survival after myocardial infarction (MI). Yet, the aging of the population counterbalances some of these advances in combatting coronary heart disease (CHD). As a result, the total economic burden of CHD may actually rise. In the US, between 1970 and 2010 hospital case-fatality for acute MI has dropped from 16.0% to 1.9% and 37.8% to 7.6% for patients aged <65 years and >65 years, respectively ([www.nhlbi.nih.gov](http://www.nhlbi.nih.gov)). The number of hospitalizations for acute MI has also declined significantly: from 53 to 25/10,000 between 1970 and 2010. The decline in death rates due to MI and stroke results in part from a reduction in hospital case fatality. The age- and sex-adjusted incidence of myocardial infarction increased from 274 cases per 100,000 person-years in 1999 to 287 cases per 100,000 person-years in 2000, and it decreased each year thereafter, to 208 cases per 100,000 person-years in 2008, representing a 24% relative decrease. A decline of ST-elevation MI (STEMI) accounts for part of the overall reduction in acute MI. The number of non ST-elevation MI (NSTEMI) and the prevalence of stable angina have changed little. Analyses of data derived from the Top 50 US based cardiovascular hospitals shows that the overall incidence of STEMI decreased by approximately 50% from 29 to 15 per 10,000 Medicare part A beneficiaries<sup>1</sup>. From 2002 to 2011, in the US the proportion of patients with MI due to NSTEMI increased from 52.8% in 2002 to 68.6% in 2011<sup>2</sup>. The downward trend in STEMI continues not only in most EU based countries but also in the Middle East. For example, in an Israeli study a decline in the incidence of acute coronary syndrome admissions (per-1000 persons) was reported between 2002 vs. 2012 for STEMI: 4.70 vs. 1.38 (p<0.001) and non-significant tendency of increase for NSTEMI: 1.86 vs. 2.37<sup>3</sup>.

Here, we will review clinical and pathological determinants that may underlie the observed secular trends in incidence and clinical presentation of myocardial infarction.

Risk factor modification and altered incidence of acute cardiovascular atherosclerotic events.

The explanations for the decline in cardiovascular mortality and disease may differ geographically. The Global Burden of Disease 2010 Study described regional differences in the time trends in the incidence of ischemic heart disease for 21 regions in the world <sup>4</sup>. Lifestyle changes such as improved nutrition and less smoking and/or treatment of risk factors such as blood pressure and high cholesterol have influenced death rates differentially among countries <sup>5</sup>. Experiments of nature and secular economic trends suggest that changes in dietary caloric intake in countries significantly lowers cardiovascular mortality <sup>6</sup>.

National regulatory agencies are actively changing policies to reduce the use of unnecessary food additives that influence health. Addition of trans fats to foods and impart a desirable taste and texture. Trans-fat intake associates with higher risk of CHD<sup>7</sup>. National food agencies are restricting the use of *trans* fats in foodstuffs. The Western diet is also high in salt, originating primarily from processed foods. The U.S. Food and Drug Administration has issued proposed guidelines targeting the packaged food and restaurant meals that contain the bulk of American's daily sodium intake. The guidelines aim at bringing daily salt intake to 2,300 milligrams down from a current average of 3,400 milligrams.<sup>8</sup> Estimates suggest that reducing dietary salt by 3 g per day could reduce the annual number of myocardial infarction by more than 50,000. <sup>9</sup>

Governmentally mandated smoking policies have restricted public smoking dramatically, and consequently yielded a major reduction in exposure to passive smoking <sup>10 11 12 13</sup>. The timing of banning of smoking in restaurants resulted in a decrease in hospitals admissions for STEMI between 5-20%. The non-smoking population accounted for this decline, while the number of infarctions in the smoking group remained stable <sup>13</sup>.

The widespread increase in the use of cholesterol-lowering drugs, notably the statins, has also altered the risk factor landscape tremendously. The 2013 guideline of the ACC/AHA recommends statin use for all individuals with a risk of >7.5% suffering from a MI or stroke in 10 years <sup>14</sup>. This evidence-based guideline aimed to allocate statins to high-risk patients who

harbor a greater burden of atherosclerosis and followed a process of shared decision making between patient and clinician<sup>15</sup>. The application of this guideline might prevent as many as 450,000 atherosclerotic cardiovascular disease events over 10 years<sup>16</sup>.

The effective use of antihypertensive drugs over the last decade has also increased. Blood pressure associates strongly with risk for stroke and for coronary artery disease as well. A strong evidence base supports the efficacy of the management of hypertension in managing stroke risk and that of MI as well. For each 5 mm Hg reduction in systolic blood pressure, cardiovascular risk falls by 17% with little difference according antihypertensive medication class<sup>17 18</sup>. Single and dual antiplatelet therapy another category of pharmaceutical treatment of growing use in secondary prevention and in some high risk individuals in primary prevention in accord with current guidelines may also contribute to reductions in the rate of MI<sup>19 20</sup>.

Beneficial changes in diet, life style and medical treatment will have certainly contributed to the decline in STEMI incidence. However, in Western society the average body mass index and diabetes incidence have increased significantly over the last decades that may counterbalance the currently observed decline of MI and stroke. However, it must be noted that obesity increases are slowing<sup>21</sup>. Despite the encouraging drop in age-adjusted cardiovascular mortality and morbidity, the ageing population portends an absolute increase in this burden. In US, some projections predict a rise in total coronary and stroke deaths by 2030 of ≈18%. Deceleration is already observed in the decline of all cardiovascular and stroke mortality rates since 2011.<sup>22</sup> However, the models used for this prediction have engendered debate, since taking into account continued secular trends toward risk factor reduction, coronary mortality may further decrease by 2030 by ≈27% with stroke mortality remaining unchanged.<sup>23</sup>

Controversy persists regarding the body mass index that confers the lowest risk for cardiovascular disease and mortality. Although average body mass index has increased over time in most countries, the overall prevalence of cardiovascular risk factors may also be decreasing among obese individuals over time. Indeed, in 3 Danish cohorts, the body mass index associated with the lowest all-cause mortality increased by 3.3 kg/M<sup>2</sup> from cohorts enrolled from 1976-1978 through 2003-2013.<sup>24</sup>

Age predominates as a risk factor for the development of CHD. Indeed, CHD now first presents in older individuals. Analyses of advanced atheromata show that age associates strongly with elevated inflammatory and proteolytic activity<sup>25</sup>.

#### *Diagnosis of MI and reclassification of patients*

Only a minority of individuals who present for urgent care for chest complaints actually receive a diagnosis of MI. Early diagnosis is essential to differentiate between patients who require invasive treatment to preserve cardiac function and identify patients who can be discharged with low risk. High sensitivity cardiac troponin assays now serve diagnosis of MI even within the first hour of presentation<sup>26 27 28 29</sup>. The advent of more sensitive troponin measurements will doubtless lead to reclassification of “unstable angina” to NSTEMI, contributing part of the persistence of NSTEMI while STEMI rates decline<sup>30 31</sup>. It merits consideration that European and US guidelines differ in the strength of recommendation regarding the use of high sensitive Troponin in the diagnosis of NSTEMI<sup>32</sup>.

#### *Secular trend in clinical presentation and the atherosclerotic plaque.*

Improved risk factor control associates with the lower incidence of MI and stroke but does it contribute to the reported atherosclerotic lesion “stabilization” and the subsequent shift in clinical presentation from STEMI to NSTEMI? Serial imaging and pathological studies revealed that statin treatment reduces lipid content and increases the relative collagen content of human plaques, features thought to stabilize lesions<sup>33 34 35–37</sup>. These alterations in human plaque morphology correspond well with the changes in lesion characteristics induced by lipid-lowering by diet or by statins in experimental animals<sup>38</sup>. Whether curbs of smoking or the use of antihypertensive drugs produce similar effects on atherosclerotic plaque characteristics has received little attention.

The presenting clinical symptoms of coronary artery disease or cerebral ischemia may reflect the underlying pathological mechanism that leads to the ischemic event. Much of our thinking in this regard over the last decades has focused on the concept of the “vulnerable plaque.” Largely based on autopsy studies performed in the latter decades of the 20<sup>th</sup> century, this formulation has proven highly useful as a guide for research and understanding



of the pathophysiology of the acute coronary syndromes (ACS). Yet, current data suggest that the observed shift in the acute clinical manifestations of coronary heart disease (CHD) reflects a concomitant change in the underlying pathological substrates. These considerations prompt a reevaluation of the relative importance of the so-called “vulnerable plaque” in the current era.

### **The concept and pathophysiology of the vulnerable plaque**

Atherosclerosis causes clinical disease through luminal narrowing or by precipitating thrombi or atheroemboli that impede blood flow to the heart, brain or lower extremities.

Histopathological studies of coronary arteries of patients who died of acute MI revealed that large atheroma size, a thin fibrous cap, and the presence of abundant inflammatory cells (mainly macrophages) characterize culprits of fatal thrombotic events<sup>39 40 41</sup>. The pathophysiological role of calcium in plaque destabilization may be a double edged sword. Calcified noduli may protrude in the lumen with subsequent thrombus formation<sup>42</sup>. On the other hand calcification may represent “plaque healing” since calcium density relates inversely with CHD and statin use promotes atheroma calcification<sup>43,44</sup>. The pioneering post-mortem studies disclosed that “vulnerable plaques” caused about two-thirds to three-fourths of fatal acute MIs by engendering thrombosis due to a fracture of the plaque’s fibrous cap. The “vulnerable plaque” concept has inspired the work of legions of vascular biology researchers. Such lesions became a target for imaging, drug discovery, and quest to mimic plaque rupture in animal experiments.

Yet, despite the value of the “vulnerable plaque” construct in orienting our understanding of the mechanisms of ACS, the concept has encountered challenges, and may apply less to the current era than during the prior period when post mortem studies identified it as a key mechanism of MI. This reevaluation has become timely given the shift in clinical presentations of patients with ACS from a dominance of STEMI to non-STEMI.

Not only have we witnessed a shift in ACS mechanisms, but in stable coronary artery disease as well. We lack sufficient autopsy studies on plaques that cause more stable coronary syndromes, and insights into the pathogenesis of stable coronary syndromes derives mostly from in vivo imaging studies. Compared to patients presenting with acute MI, those with stable angina tend to have less coronary arterial plaque burden, less expansive remodeling,

less abundant evidence of inflammation and neovascularization, and fewer thrombi<sup>45 46</sup>.

Furthermore, although analysis at autopsy of culprit lesions responsible for most acute coronary syndromes have revealed plaque rupture, a proportion of occlusive thrombi complicate lesions that lack the typical thin-capped characteristics of ruptured lesions, a morphologic appearance denoted “superficial erosion”<sup>47 48</sup>. These non-ruptured thrombotic lesions occur more frequently observed in women, particularly younger women. Indeed, in females such eroded lesions may cause up to 50% of acute coronary deaths<sup>47</sup>. In males, up to 25% of acute coronary deaths may originate from non-ruptured, eroded lesions.

Pathological and in vivo imaging studies suggest that the change in clinical presentation of ACS towards more NSTEMI correlates temporally with a lower prevalence of thrombosis provoked by ruptured plaques. NSTEMI patients have a much lower prevalence of ruptured plaques (43%) than do those with STEMI (71 %) (Table 1). The evolution in the characteristics of atherosclerotic disease may reflect not only secular trends in risk factors and therapeutic interventions, but also demographic shifts in the patients enrolled in studies. Indeed, both trends may contribute to the changes in time in atherosclerosis that we highlight here.

Another major challenge to the “vulnerable plaque” concept arises from the findings that lesions with the histological characteristics associated with “vulnerability” commonly occur in atherosclerotic arteries in the absence of clinically manifest disease. Some ¾ of femoral and coronary atheromata in individuals without acute manifestations show signs of inflammation in their cap and shoulder<sup>49</sup>. Leukocyte activation markers rise in the venous effluent from regions not supplied by the culprit lesions in patients with ACS<sup>50</sup>. Less than 5% of coronary artery plaques characterized as thin-capped fibroatheromata by intravascular imaging cause an acute event during a more than 3 year follow-up period, as shown in the Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) study.<sup>51</sup> Thus, the vast majority of so-called “vulnerable plaques” are actually quite stable. Moreover, the data reviewed above support the dispersed and multiple nature of such lesions, challenging the validity of approaches that aim to identify and treat locally an isolated vulnerable plaque<sup>52</sup>.

**The cross-talk between the plaque and the circulation: It takes two to tango**

In PROSPECT, circulating C-reactive protein (CRP) concentrations strongly predicted the rate of major adverse coronary events: 13.8% of thin cap fibroatheromatous non-culprit lesions associated with a major adverse event during follow up in for patients with very elevated (>10mg/L), compared with only 1.9% in those with lower CRP (<3 mg/L). The number of high-risk thin cap fibroatheromatous non-culprit plaques did not differ between the high and low CRP groups. This study strengthens the view that in the absence of augmented inflammation revealed by elevation of this marker, few of these lesions provoke an event<sup>53</sup>.

Indeed, the thin-capped morphology ascribed to “vulnerable plaques” has limited positive predictive value for the occurrence of an acute event. Fully 105 plaque ruptures in 100 coronary arteries complicated lesions that lacked the so-called “vulnerable morphology” interrogated by virtual histology/IVUS in PROSPECT. During a 3 year follow up the incidence of major adverse cardiac events did not differ between the patients with and those without subclinical, non-culprit plaque ruptures.<sup>54</sup> Thus, the consequences of a plaque disruption depend not only on the ‘solid state’ of atheroma itself, but involve the presence of other etiological determinants such as the coagulation status of the blood.<sup>55</sup> Coronary CT follow-up studies observed an almost identical number of acute coronary syndromes associated with the presence of high risk plaques (with positive remodeling and low attenuation) and those characterized as “low risk” plaques<sup>56</sup>. In addition, not only the instantaneous morphologic characteristics of a lesion but its dynamics critically influence the propensity to provoke an MI<sup>57 58</sup>. Rapid progression of lesion size could result from intraplaque bleeding, a feature of plaques predictive of future adverse events, but one not included in the current definitions of the vulnerable plaque<sup>59 60</sup>.

### **Time dependent changes in plaque characteristics that underlie cardiovascular ischemic events.**

The concept of the vulnerable plaque also requires adjustment as the characteristics of the human plaque evolve in time, in synchrony with the shifts in the clinical presentation and risk profile of patients with ACS. A substantial decline in the incidence of fatal stroke accompanies this evolution in the thrombotic complications of coronary artery plaques<sup>61 62</sup><sup>63</sup>. These tandem temporal changes in coronary and cerebral events suggest a systemic rather than a local change in atherosclerotic disease progression. Athero-Express, an

ongoing Dutch study, has collected atherosclerotic carotid plaques since 2002<sup>64</sup>. Analyses of retrieved atherosclerotic plaque specimens in the Athero-Express biobank have revealed a clear shift in the characteristics of human atherosclerotic plaques over time<sup>65</sup>. Features that characterize the “vulnerable plaque” such as atheroma size, lipid content, intraplaque hemorrhage, calcifications, and the number of inflammatory cells have decreased markedly in plaques collected more recently. The percentage of carotid plaques with intraplaque hemorrhages decreased from 70% in 2002 to 35% in 2011, concomitantly plaques with large lipid pools fell from 30% to 15%<sup>65</sup> (Figure 2). The time dependent shift from plaques with histological features associated with ‘instability’ toward those with characteristics generally ascribed to “stable” plaques occurred in lesions retrieved from either symptomatic or asymptomatic patients. Thus, it appears that there is not just a time dependent decline in major cardiovascular event rates, but even within the remaining diseased but event-free or asymptomatic patient group, the character of plaques has shifted in just the last dozen or so years towards features associated with “stability.”

*Are we facing a paradigm shift in the pathogenetic basis of acute thrombotic atherosclerotic events?*

The following observations argue in favor of the proposition that the cardiovascular clinical and investigative communities face a transition that challenges the current view of the prevailing mechanisms that underlie the acute major clinical events due to atherosclerotic disease. 1-The decline in death rate and hospitalisations due to acute coronary syndromes and stroke, 2- The relative increase in NSTEMI versus STEMI in patients presenting with an ACS (Figure 1) and 3-The changes in plaque characteristics of culprit lesions that underlie the acute thrombotic complications that cause stroke and ACS. (Figures 1, 2).

This transition in mechanisms of disease in symptomatic patients coincides with a temporal transition in total atherosclerotic disease burden in the general population. In diagnostic procedures the rate of abnormal SPECT studies impressively declined from 40.9% in 1991 to 8.7% in 2009<sup>66</sup>. This transition appears to continue, and the search for mechanistic explanations has potentially critical consequences for clinical practice, for public health, and for future research directions.

### Plaque erosion: What is in a name?

What morphological, cellular, and molecular features of the non-ruptured atherosclerotic lesion might provoke thrombotic events? As noted above, thrombotic events can arise from fibrous atheromata that lack a thin fibrous cap by a mechanism distinct from fracture generally denoted plaque erosion. The phrase erosion suggests that a dysfunctional or absent layer of endothelium promotes thrombosis. The mechanisms of such an erosive event have received scant attention. Endothelial apoptosis can induce arterial thrombosis in rabbits providing one possible mechanism of plaque erosion<sup>67</sup>. Inflammatory cell recruitment might accelerate this process, although most, but not all, studies find few inflammatory cells within lesions complicated by thrombosis attributed to superficial erosion.<sup>40,68</sup> In vitro experiments found that mast cell release of chymase together with TNF-alpha can induce endothelial apoptosis.<sup>69</sup> An observational study in human coronary segments showed co-localisation of subendothelial mast cells and intraluminal platelet microthrombi suggesting that desquamation of the endothelium by mast cell proteases induce activation of the endothelium<sup>70</sup>. Endothelial cells can generate endogenous reactive oxygen species (ROS) that subsequently promote cell death. Various pro-inflammatory and pro-atherosclerotic factors such as Angiotensin II and TNF-alpha can induce ROS generation by endothelial cells<sup>71</sup>.

The neutrophil cell lineage may also participate in plaque thrombosis without rupture, although likely in a second wave, after initiation of the process<sup>72</sup>. Neutrophils contain abundant myeloperoxidase, a pro-oxidant enzyme that circulates at higher concentrations in patients with acute coronary syndrome due to an eroded culprit lesion compared with patients with a ruptured culprit plaque as defined by optical coherence tomography. In addition, luminal thrombi on eroded coronary artery plaques at postmortem examination contain more myeloperoxidase-positive cells than thrombi caused by ruptured plaques, suggesting the presence of neutrophils<sup>73</sup>. Neutrophils can elaborate strands of DNA, called neutrophil extracellular traps (NETs.) These extracellular DNA strands can promote primary and secondary hemostasis by inducing platelet aggregation and activation of coagulation. In addition, NETs may inhibit fibrinolysis and thereby enhance clot stability. Neutrophil recruitment to the vessel wall, and subsequent NET generation can contribute to a highly pro-coagulant environment that could amplify, propagate, and sustain arterial thrombi<sup>74</sup>.

*Less lethal coronary artery disease and altered mechanisms of thrombotic events: possible clinical and research implications*

The evolving characteristics of atherosclerotic plaques that cause clinical manifestations in contemporary practice provides an alert that the research community needs to update thinking regarding the current clinically relevant mechanisms of the thrombotic complications of atherosclerosis. A multitude of experimental studies, most often using genetically modified mice with exaggerated cholesterol concentrations, refer to the effects of various genetic or pharmacologic manipulations on what publications often refer to as "stable" or "unstable" plaque "phenotype." The current human pathological and clinical findings reviewed here cast serious doubt on the applicability of such studies to contemporary clinical practice. Indeed, the ongoing shift in the incidence in atherosclerotic disease manifestations, and the responsible pathological substrate require consideration in the interpretation of many past basic, translational and clinical studies. Extrapolation of observations from the last century, obtained in a bygone era of therapy and risk factor exposure, warrants a re-evaluation of the key current questions for research, and the interpretation of experimental results. The section below discusses the potential implications of the currently shifts in clinical manifestations and pathogenesis of atherosclerotic disease.

*Population and cohort based biobanks initiated over 10 years ago.*

The decline in age-adjusted incidence of events due to atherosclerosis, the altered risk profiles, and the increased use of highly effective preventive medications calls into question the relevance to today's disease of plaque or blood specimens banked frozen for future research purposes in past decades. The translational value of observations made on such materials for current practice raise even further concern if both the sampling of specimens and the monitoring of cardiovascular events took place more than a decade ago. Circulating biomarkers that add to the prediction of the progression of atherosclerotic disease and inform regarding the effects of novel therapies still comprise an unmet need<sup>75 76 77</sup> The concept that acute atherosclerotic events commonly complicate highly inflammatory and proteolytic plaques has driven many biomarker discovery programs. Many proposed

biomarkers with predictive value for MI such as myeloperoxidase<sup>78</sup>, high sensitive C reactive protein, and soluble ICAM<sup>79</sup> arise from the idea that vascular inflammation participates pivotally in the pathogenesis of cardiovascular events. While this concept has served the community well, and derives support from a large body of consistent studies, this formulation may apply less to a growing group of patients with ischemic heart disease receiving *current* standard of care treatments. In Utrecht, a study exploring the determinants of cardiovascular events has enrolled patients with any kind of manifestations of atherosclerotic disease since 1995<sup>80</sup>. This study observed a consistent decline in CRP concentrations over time (Figure 3). These considerations indicate that the time window of enrollment and of blood sampling can influence profoundly the observational associations between biomarkers, the burden of atherosclerotic disease, and clinical events.

#### *Imaging of the atherosclerotic plaque at risk*

The pathological observations that delineated the characteristics of the rupture prone plaque, the thin capped fibroatheroma, has inspired a legion of quests to develop imaging modalities to assess such lesions in vivo. Ultrasound based “virtual histology”<sup>81</sup>, Raman spectroscopy<sup>82</sup>, thermography<sup>83</sup> near-infrared spectroscopy<sup>84</sup> or optical coherence tomography<sup>85 86</sup>, and a variety of molecular imaging strategies have all undergone development seeking to detect the inflammatory thin cap fibroatheroma, the type of plaque supposed to entail a high risk for a thrombotic event based on the pathological observations from the last century. Non-invasive magnetic resonance imaging can identify intraplaque hemorrhage, a plaque characteristic that may predict future adverse cardiovascular events and progression of luminal narrowing<sup>87 60</sup>. Imaging of features that associate with the classically defined thin cap fibroatheroma may help to assess the efficacy of plaque stabilizing drugs. Yet, the community should take into account secular trends in atheroma as therapy has advanced. For example, atorvastatin vs. pravastatin produced a reduction in carotid intima-media thickness in the ASAP study reported in 2001, but the addition of ezetimibe did not decrease this variable in the ENHANCE trial reported in 2008. At present carotid intima media thickness may be challenged when used as a measure of drug efficacy, but this result might have arisen because of application of standard of care in the interim

lowered the baseline intima-media thickness to the “normal” range, obscuring the possible effect of the additional therapy.<sup>88 89</sup> The lower incidence of STEMI and the concomitant increase in less lipid laden and inflamed plaques in the statin era raise similar notes of caution regarding the interpretation of and goals of imaging studies. Others share this view, refer to “the myth of the vulnerable plaque”, and propose that the management of patients at risk of MI mandates a greater focus on atherosclerotic disease burden than on features of individual plaques<sup>52</sup>, an inference that derives support from studies with coronary computed tomography angiography in patients with non-obstructive coronary artery disease<sup>90</sup>.

### Cardiovascular risk scores used to predict the absolute risk of cardiovascular events

Various proposed cardiovascular risk scores predict the risk for future primary events and stratify patients into low, intermediate and high-risk categories. As a community we have generally targeted the most aggressive risk factor management to higher risk individuals. Risk scores such as the Framingham risk score, have served as a comparator to explore the added value of novel biomarkers on top of traditional risk factors for the prediction of coronary heart disease<sup>91</sup>. The arguments presented here, notably regarding the trend toward less STEMI and altered characteristics of culprit plaques, may impact the current clinical relevance of the most widely applied cardiovascular risk scores. Most population based cohorts that have provided event rates for risk assessment in these studies underwent a follow up of at least 10-12 years, and included individuals whose had blood sampled before 1990 or as far back as the 1960s. At inclusion these individuals were almost certainly exposed to different risk factors, medical treatments, more passive smoking and nutritional and other life style measures than contemporary cohorts. Moreover, clinical endpoints in prior eras included more STEMI, higher case fatality rates for ACS, and as argued here, an underlying pathological substrate that has shifted as compared to nowadays. The consequence of the application of cohorts sampled in prior eras for risk score assessment has contributed to the recent debate regarding the use of statins based on the new AHA-ACC-ASCVD risk scores<sup>92</sup>. The newly developed risk scores proposed by the ACC/AHA guidelines may overestimate cardiovascular events by 37% to 154% in men and 8% to 67% in women when discrimination and calibration was compared with other risk scores and the



actual observed events<sup>93</sup>. Cardiovascular risk scores should undergo external validation in current populations before their clinical implementation. One contribution to this controversy could be the use of external validation cohorts sampled more recently than those used to derive the risk prediction algorithm, and that therefore reflect secular improvements in overall health and lifestyle patterns<sup>92</sup>. Indeed, the cohorts used for the newly developed ACC-AHA risk prediction models originated from cohorts assembled before 1990. Risk prediction algorithms should not only discriminate between individuals with and without disease, but must also calibrate well so that predicted risk estimates match as closely as possible the observed risk in external populations<sup>94</sup>. In a recent editorial on a report that clearly showed that the ACC/AHA Pooled Risk Equation substantially overestimates the 5 year risk of atherosclerotic cardiovascular events<sup>95</sup>. Indeed, Blaha has argued that risk score calibration is among the most important issues in preventive cardiology<sup>96</sup>. The validation of risk instruments should use cohorts that reflect current practice as closely as possible. This goal presents a challenge since accumulation of events requires a follow up period, such that external validation uses cohorts that enrolled more than one decade ago.

#### Implications for the interpretation of animal experiments

The slow progression of human atherosclerosis hampers the study of the natural history of this disease, which would ideally involve extensive serial examinations. To provide insight into mechanisms of pathogenesis and the effects of therapies, laboratory studies generally use *in vitro* cell-based approaches or experiments in animals. The generation of genetically modified mice on an atherosclerotic background exponentially increased the published papers on genes that may influence plaque growth and lesion characteristics<sup>97 98</sup>. The interpretations of many interventions in mice often refer back to the early pathological descriptions of the “vulnerable plaque” deemed responsible for triggering most thrombotic occlusive events in humans<sup>99</sup>. Despite its undeniable utility for probing specific molecular mechanisms, atherosclerosis-prone mice differ in a multitude of important respects from humans with arterial disease<sup>100 101</sup>. A rigorous assessment of the clinical translatability of the results of investigations in atherosclerotic mice requires careful and deliberate consideration of these concerns. In particular, the profound effects of current clinical standard of care on human atherosclerotic lesions and their clinical consequences may

amplify the distance between the exaggerated experimental conditions usual in mouse studies of atherosclerosis and patients with this chronic condition now usually receiving multiple medical interventions and often harboring co-morbidities not modeled in mice. Few established experimental approaches described in animals aim to mimic aspects of spontaneous luminal thrombus formation on stable atherosclerotic plaques.<sup>102</sup>

## Conclusions

In medicine, as in many other pursuits, we should strive to keep eyes on a moving target. The edifice of the “vulnerable plaque” arose from a foundation as firm as any in science. We celebrate justly the strides we have made in mastering the lipid-rich atheromatous plaque, from both a pathophysiologic and therapeutic perspective. The benefits that have emerged from these advances for public health merit considerable celebration. The last decades we have enjoyed the rare privilege of witnessing extraordinary inroads against atherosclerotic disease, akin to the transformative effect of the introduction of antibiotics on infective diseases.

Yet, the very measures that have enabled our extraordinary success in improving clinical outcomes in those at risk, have altered the disease itself. Moreover, the improved understanding and treatment of classical risk factors for atherosclerosis, has occurred in the face of a countervailing worldwide increase in obesity and dysmetabolism that may drive the next wave of epidemic cardiovascular disease. These concerns preclude premature celebration of victory against atherosclerotic disease. To confront the residual burden of disease in an era of highly effective LDL lowering, societal measures to combat tobacco abuse, and the widespread availability of strategies for management of hypertension, we must prepare to wage battle against the disease of today and tomorrow, not that of yesteryear. We can take heart in our success in lowering total plaque burden and taming the “vulnerable plaque,” and now turn our attention to combatting residual risk in the current era with the same energy and enthusiasm that brought us to this “tipping point” in the disease. To meet this challenging objective we will need to reconsider the implications for current practice of findings collected before new millennium, and all of the changes in therapy and the risk factor environment that have ensued. Biomarker and drug target discovery programs should interpret with caution data derived from samples that were

obtained >10-15 years ago, risk scores should be calibrated studying cohorts that resemble the current population, and development of imaging modalities should reach beyond the characteristics of the so-called vulnerable lesion, and embrace more fully gauging total plaque burden.

	Clinical presentation	% with rupture	% no rupture	Number included	ref
Pathology	Death due to ACS	75	25	291	48
Pathology	Sudden death	56	44	50	47
Pathology	Sudden death	69	31	59	103
OCT	STEMI	72	28	53	104
OCT	STEMI	70	30	40	105
OCT	STEMI	64	36	47	106
OCT	STEMI	83	17	24	107
OCT	STEMI	66	34	95	108
OCT	STEMI	72	28	53	109
OCT	STEMI	71	29	102	110
OCT	STEMI	64	36	14	111
OCT	STEMI	60	40	62	112
IVUS/atherectomy	STEMI	83	17	54	113
OCT	NSTEMI	49	51	110	104
OCT	NSTEMI	19	81	43	114
OCT	NSTEMI	47	53	49	105
OCT	NSTEMI	57	43	92	106
OCT	NSTEMI	46	54	83	107
OCT	NSTEMI	40	60	40	109
OCT	NSTEMI/UA	33	66	24	111
IVUS/atherectomy	NSTEMI	25	75	40	113





Table 1 and summarizing figure. There is an evident shift in clinical presentation over time with lower incidence of STEMI and an increased proportion of patients presenting with NSTEMI. This table reflect subsequent changes in plaque characteristics underlying luminal occlusive thrombosis. Pathology and optical coherence tomography (OCT) studies report a plaque rupture in 71% of the lesions of patients presenting with sudden death, death due to an acute coronary syndrome or presenting with STEMI (figure depicted red). In NSTEMI patients approximately 43% of the culprit lesions reveal a plaque rupture on OCT. Data in the figure are obtained and calculated from references mentioned in the Table.



*Figure 1. A decline in total death rate and hospitalizations following ACS and acute stroke has occurred over time. A fall in the incidence of STEMI accompany these clinical trends and a contemporaneous shift in the characteristics of human atherosclerotic plaques away from those associated with “vulnerability” or plaque rupture. The rise in use of antihypertensive medication, cholesterol lowering treatment, anti platelet therapy and risk factor management has likely contributed to this secular trend. Banning of smoking by governmental policy strongly influenced the risk of passive smoking.*

## Shifts in the composition of human atheromata from 2002-2003 to 2010-2011




Figure 2. The changes in plaque composition over time observed in carotid arterial plaques that have been dissected by endarterectomy.




Figure 3. C-reactive protein levels in patients who have been included in the SMART study and have been diagnosed with either carotid, coronary or peripheral artery disease in the University Medical Center Utrecht <sup>58</sup>.

## References

1. Truven health analytics. at <[https://100tophospitals.com/Portals/2/assets/TOP\\_15192\\_1214\\_AMITrends\\_WEB.PDF](https://100tophospitals.com/Portals/2/assets/TOP_15192_1214_AMITrends_WEB.PDF)>
2. Khera, S. *et al.* Non-ST-elevation myocardial infarction in the United States: contemporary trends in incidence, utilization of the early invasive strategy, and in-hospital outcomes. *J. Am. Heart Assoc.* **3**, (2014).
3. Plakht, Y., Gilutz, H. & Shiyovich, A. Temporal trends in acute myocardial infarction: What about survival of hospital survivors? Disparities between STEMI & NSTEMI remain. Soroka acute myocardial infarction II (SAMI-II) project. *Int. J. Cardiol.* **203**, 1073–1081 (2016).
4. Moran, A. E. *et al.* The global burden of ischemic heart disease in 1990 and 2010: The global burden of disease 2010 study. *Circulation* **129**, 1493–1501 (2014).
5. Ford, E. S. & Capewell, S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. *Annu. Rev. Public Health* **32**, 5–22 (2011).
6. Franco, M. *et al.* Impact of energy intake, physical activity, and population-wide weight loss on cardiovascular disease and diabetes mortality in Cuba, 1980–2005. *Am. J. Epidemiol.* **166**, 1374–1380 (2007).
7. Guasch-Ferré, M. *et al.* Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease. *Am. J. Clin. Nutr.* **102**, 1563–73 (2015).
8. Nutrition, C. for F. S. and A. Consumers - Sodium in Your Diet: Use the Nutrition Facts Label and Reduce Your Intake. at <<http://www.fda.gov/Food/ResourcesForYou/Consumers/ucm315393.htm>>
9. Bibbins-Domingo, K. *et al.* Projected effect of dietary salt reductions on future cardiovascular disease. *N. Engl. J. Med.* **362**, 590–9 (2010).
10. Seo, D. C. & Torabi, M. R. Reduced admissions for acute myocardial infarction associated with a public smoking ban: matched controlled study. *J Drug Educ* **37**, 217–226 (2007).
11. Juster, H. R. *et al.* Declines in hospital admissions for acute myocardial infarction in New York state after implementation of a comprehensive smoking ban. *Am J Public Heal.* **97**, 2035–2039 (2007).
12. Sargent, R. P., Shepard, R. M. & Glantz, S. A. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. *BMJ* **328**, 977–80 (2004).
13. Schmucker, J. *et al.* Smoking ban in public areas is associated with a reduced incidence of hospital admissions due to ST-elevation myocardial infarctions in non-smokers. Results from the Bremen STEMI Registry. *Eur. J. Prev. Cardiol.* **21**, 1180–6 (2014).
14. Stone, N. J. *et al.* 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J. Am. Coll. Cardiol.* **63**, 2889–934 (2014).
15. Martin, S. S. *et al.* Clinician-patient risk discussion for atherosclerotic cardiovascular disease prevention: importance to implementation of the 2013 ACC/AHA Guidelines. *J. Am. Coll. Cardiol.* **65**, 1361–8 (2015).
16. Robinson, J. G. & Stone, N. J. The 2013 ACC/AHA guideline on the treatment of blood



- cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. *Eur. Heart J.* **36**, 2110–2118 (2015).
17. Ninomiya, T. *et al.* Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. *BMJ* **347**, f5680 (2013).
  18. Herrington, W., Lacey, B., Sherliker, P., Armitage, J. & Lewington, S. Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. *Circ. Res.* **118**, 535–546 (2016).
  19. Vandvik, P. O. *et al.* Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* **141**, e637S–e668S (2012).
  20. Udell, J. A. *et al.* Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. *Eur. Heart J.* **37**, 390–9 (2016).
  21. Ferranti, de S., J-p, D. & Iii, M. E. Heart Disease and Stroke statistics 2016 update. [https://www.heart.org/idc/groups/ahamh-public/@wcm/@sop/@smd/documents/downloadable/ucm\\_480110.pdf](https://www.heart.org/idc/groups/ahamh-public/@wcm/@sop/@smd/documents/downloadable/ucm_480110.pdf)  
doi:10.1161/CIR.0000000000000350
  22. Sidney, S. *et al.* Recent Trends in Cardiovascular Mortality in the United States and Public Health Goals. *JAMA Cardiol.* (2016). doi:10.1001/jamacardio.2016.1326
  23. Pearson-Stuttard, J. *et al.* Modelling Future Cardiovascular Disease Mortality in the United States: National Trends and Racial and Ethnic Disparities. *Circulation* **133**, 967–78 (2016).
  24. Afzal, S., Tybjaerg-Hansen, A., Jensen, G. B. & Nordestgaard, B. G. Change in Body Mass Index Associated With Lowest Mortality in Denmark, 1976–2013. *JAMA* **315**, 1989 (2016).
  25. van Oostrom, O. *et al.* Age-related changes in plaque composition: A study in patients suffering from carotid artery stenosis. *Cardiovasc. Pathol.* **14**, 126–134 (2005).
  26. Keller, T. *et al.* Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction. *N Engl J Med* **9361**, 868–77 (2009).
  27. Reichlin, T. *et al.* Prospective validation of a 1-hour algorithm to rule-out and rule-in acute myocardial infarction using a high-sensitivity cardiac troponin T assay. *CMAJ* **187**, E243–52 (2015).
  28. Shah, A. S. V *et al.* High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. *Lancet (London, England)* **386**, 2481–8 (2015).
  29. Neumann, J. T. *et al.* Diagnosis of Myocardial Infarction Using a High-Sensitivity Troponin I 1-Hour Algorithm. *JAMA Cardiol.* **1**, 397–404 (2016).
  30. Schofer, N. *et al.* Gender-specific diagnostic performance of a new high-sensitivity cardiac troponin I assay for detection of acute myocardial infarction. *Eur. Hear. journal. Acute Cardiovasc. care* (2016). doi:10.1177/2048872615626660
  31. D’Souza, M. *et al.* Diagnosis of Unstable Angina Pectoris Has Declined Markedly with the Advent of More Sensitive Troponin Assays. *Am. J. Med.* **128**, 852–860 (2015).
  32. Rodriguez, F. & Mahaffey, K. W. Management of Patients With NSTEMI-ACS. *J. Am. Coll. Cardiol.* **68**, 313–321 (2016).
  33. Underhill, H. R. *et al.* Effect of rosuvastatin therapy on carotid plaque morphology and

- composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. *Am. Heart J.* **155**, (2008).
34. Crisby, M. *et al.* Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. *Circulation* **103**, 926–33 (2001).
  35. Puri, R. *et al.* Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: Insights from SATURN. *Eur. Heart J. Cardiovasc. Imaging* **15**, 380–388 (2014).
  36. Libby, P. How does lipid lowering prevent coronary events? New insights from human imaging trials. *European Heart Journal* **36**, 472–474 (2015).
  37. Park, S. J. *et al.* Effect of Statin Treatment on Modifying Plaque Composition A Double-Blind, Randomized Study. *J. Am. Coll. Cardiol.* **67**, 1772–1783 (2016).
  38. Libby, P. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. *N. Engl. J. Med.* **368**, 2004–2013 (2013).
  39. Davies, M. J. & Thomas, A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. *N. Engl. J. Med.* **310**, 1137–1140 (1984).
  40. van der Wal, a C., Becker, a E., van der Loos, C. M. & Das, P. K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation* **89**, 36–44 (1994).
  41. Falk, E. precipitating coronary thrombosis Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. *Br. Heart J.* **50**, 127–134 (1983).
  42. Virmani, R., Kolodgie, F. D., Burke, A. P., Farb, A. & Schwartz, S. M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. *Arterioscler. Thromb. Vasc. Biol.* **20**, 1262–75 (2000).
  43. Criqui, M. H. *et al.* Calcium density of coronary artery plaque and risk of incident cardiovascular events. *JAMA* **311**, 271–8 (2014).
  44. Puri, R. *et al.* Impact of Statins on Serial Coronary Calcification During Atheroma Progression and Regression. *J. Am. Coll. Cardiol.* **65**, 1273–1282 (2015).
  45. Smits, P. C. *et al.* Coronary artery disease: arterial remodelling and clinical presentation. *Heart* **82**, 461–4 (1999).
  46. Tian, J. *et al.* Significance of intraplaque neovascularisation for vulnerability: optical coherence tomography study. *Heart* **98**, 1504–1509 (2012).
  47. Farb, A. *et al.* Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. *Circulation* **93**, 1354–63 (1996).
  48. Arbustini, E. *et al.* Plaque erosion is a major substrate for coronary thrombosis in acute myocardial infarction. *Heart* **82**, 269–72 (1999).
  49. Pasterkamp, G. *et al.* Inflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteries. *Arterioscler. Thromb. Vasc. Biol.* **19**, 54–58 (1999).
  50. Buffon, A. *et al.* Widespread coronary inflammation in unstable angina. *N. Engl. J. Med.* **347**, 5–12 (2002).
  51. Stone, G. W. *et al.* A prospective natural-history study of coronary atherosclerosis. *N. Engl. J. Med.* **364**, 226–235 (2011).
  52. Arbab-Zadeh, A. & Fuster, V. The Myth of the ‘Vulnerable Plaque’: Transitioning From a Focus on Individual Lesions to Atherosclerotic Disease Burden for Coronary Artery

- Disease Risk Assessment. *J. Am. Coll. Cardiol.* **65**, 846–855 (2015).
53. Kelly, C. R. *et al.* Relation of C-reactive protein levels to instability of untreated vulnerable coronary plaques (from the PROSPECT study). *Am. J. Cardiol.* **114**, 376–383 (2014).
  54. Xie, Y. *et al.* Clinical outcome of nonculprit plaque ruptures in patients with acute coronary syndrome in the PROSPECT study. *JACC Cardiovasc. Imaging* **7**, 397–405 (2014).
  55. Libby, P. & Theroux, P. Pathophysiology of coronary artery disease. *Circulation* **111**, 3481–3488 (2005).
  56. Motoyama, S. *et al.* Plaque Characterization by Coronary Computed Tomography Angiography and the Likelihood of Acute Coronary Events in Mid-Term Follow-Up. *J. Am. Coll. Cardiol.* **66**, 337–346 (2015).
  57. Ahmadi, A. *et al.* Do Plaques Rapidly Progress Prior to Myocardial Infarction?: The Interplay between Plaque Vulnerability and Progression. *Circulation Research* **117**, 99–104 (2015).
  58. Yokoya, K. *et al.* Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. *Circulation* **100**, 903–909 (1999).
  59. Takaya, N. *et al.* Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: A high-resolution magnetic resonance imaging study. *Circulation* **111**, 2768–2775 (2005).
  60. Hellings, W. E. *et al.* Composition of carotid atherosclerotic plaque is associated with cardiovascular outcome: a prognostic study. *Circulation* **121**, 1941–50 (2010).
  61. Koton, S. *et al.* Stroke incidence and mortality trends in US communities, 1987 to 2011. *Jama* **312**, 259–68 (2014).
  62. Vaartjes, I., O’Flaherty, M., Capewell, S., Kappelle, J. & Bots, M. Remarkable decline in ischemic stroke mortality is not matched by changes in incidence. *Stroke* **44**, 591–597 (2013).
  63. Lackland, D. T. *et al.* Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. *Stroke*. **45**, 315–353 (2014).
  64. Verhoeven, B. A. N. *et al.* Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design. *Eur. J. Epidemiol.* **19**, 1127–1133 (2004).
  65. Van Lammeren, G. W. *et al.* Time-dependent changes in atherosclerotic plaque composition in patients undergoing carotid surgery. *Circulation* **129**, 2269–2276 (2014).
  66. Rozanski, A. *et al.* Temporal Trends in the Frequency of Inducible Myocardial Ischemia During Cardiac Stress Testing: 1991 to 2009. *J. Am. Coll. Cardiol.* **61**, 1054–1065 (2013).
  67. Durand, E. *et al.* In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. *Circulation* **109**, 2503–6 (2004).
  68. Saia, F. *et al.* Eroded versus ruptured plaques at the culprit site of STEMI: In vivo pathophysiological features and response to primary PCI. *JACC Cardiovasc. Imaging* **8**, 566–575 (2015).
  69. Heikkila, H. M. *et al.* Activated Mast Cells Induce Endothelial Cell Apoptosis by a

- Combined Action of Chymase and Tumor Necrosis Factor- $\alpha$ . *Arter. Thromb Vasc Biol* **28**, 309–314 (2008).
70. Mäyränpää, M. I., Heikkilä, H. M., Lindstedt, K. a, Walls, A. F. & Kovanen, P. T. Desquamation of human coronary artery endothelium by human mast cell proteases: implications for plaque erosion. *Coron. Artery Dis.* **17**, 611–21 (2006).
  71. Dimmeler, S. & Zeiher, A. M. Reactive oxygen species and vascular cell apoptosis in response to angiotensin II and pro-atherosclerotic factors. *Regul Pept* **90**, 19–25. (2000).
  72. Quillard, T. *et al.* TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: Implications for superficial erosion. *Eur. Heart J.* **36**, 1394–1404 (2015).
  73. G., F. *et al.* High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: An in vivo optical coherence tomography study. *Eur. Heart J.* **31**, 451–452 (2010).
  74. Liaw, P. C., Ito, T., Iba, T., Thachil, J. & Zeerleder, S. DAMP and DIC: The role of extracellular DNA and DNA-binding proteins in the pathogenesis of DIC. *Blood Rev.* (2015). at <<http://www.ncbi.nlm.nih.gov/pubmed/26776504>>
  75. Koenig, W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. *International Journal of Cardiology* **168**, 5126–5134 (2013).
  76. Duivenvoorden, R., de Groot, E., Stoes, E. S. G. & Kastelein, J. J. P. Surrogate markers in clinical trials-Challenges and opportunities. *Atherosclerosis* **206**, 8–16 (2009).
  77. Libby, P. & King, K. Biomarkers: A Challenging Conundrum in Cardiovascular Disease. *Arterioscler. Thromb. Vasc. Biol.* **35**, 2491–2495 (2015).
  78. Brennan, M.-L. *et al.* Prognostic value of myeloperoxidase in patients with chest pain. *N. Engl. J. Med.* **349**, 1595–604 (2003).
  79. Ridker, P. M., Hennekens, C. H., Buring, J. E. & Rifai, N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* **342**, 836–843 (2000).
  80. Simons, P. C. G., Algra, A., Van De Laak, M. F., Grobbee, D. E. & Van Der Graaf, Y. Second manifestations of ARterial disease (SMART) study: Rationale and design. *Eur. J. Epidemiol.* **15**, 773–781 (1999).
  81. Rodriguez-Granillo, G. A. *et al.* In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. *J. Am. Coll. Cardiol.* **46**, 2038–2042 (2005).
  82. Romer, T. *et al.* Histopathology of human coronary atherosclerosis by quantifying its chemical composition with Raman spectroscopy. *Circulation* **97**, 878–885 (1998).
  83. Casscells, W. *et al.* Thermal detection of cellular infiltrates in living atherosclerotic plaques: Possible implications for plaque rupture and thrombosis. *Lancet* **347**, 1447–1449 (1996).
  84. Brugaletta, S. *et al.* NIRS and IVUS for characterization of atherosclerosis in patients undergoing coronary angiography. *JACC Cardiovasc. Imaging* **4**, 647–655 (2011).
  85. Fujimoto, J. G. *et al.* High resolution in vivo intra-arterial imaging with optical coherence tomography. *Heart* **82**, 128–133 (1999).
  86. Jang, I.-K. *et al.* Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. *J. Am. Coll. Cardiol.* **39**, 604–609 (2002).
  87. Simpson, R. J. *et al.* MR imaging-detected carotid plaque hemorrhage is stable for 2

- years and a marker for stenosis progression. in *American Journal of Neuroradiology* **36**, 1171–1175 (2015).
88. Smilde, T. J. *et al.* Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. *Lancet* **357**, 577–581 (2001).
  89. Kastelein, J. J. P. *et al.* Simvastatin with or without ezetimibe in familial hypercholesterolemia. *N. Engl. J. Med.* **358**, 1431–43 (2008).
  90. Bittencourt, M. S. *et al.* Prognostic Value of Nonobstructive and Obstructive Coronary Artery Disease Detected by Coronary Computed Tomography Angiography to Identify Cardiovascular Events. *Circ. Cardiovasc. Imaging* **7**, 282–291 (2014).
  91. Wang, T. J. *et al.* Prognostic utility of novel biomarkers of cardiovascular stress: The framingham heart study. *Circulation* **126**, 1596–1604 (2012).
  92. Ridker, P. M. & Cook, N. R. Statins: new American guidelines for prevention of cardiovascular disease. *Lancet* **382**, 1762–5 (2013).
  93. DeFilippis, A. P. *et al.* An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. *Ann. Intern. Med.* **162**, 266–275 (2015).
  94. Cook, N. R. Use and misuse of the receiver operating characteristic curve in risk prediction. *Circulation* **115**, 928–935 (2007).
  95. Rana, J. S. *et al.* Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. (2016). doi:10.1016/j.jacc.2016.02.055
  96. Blaha, M. J. The Critical Importance of Risk Score Calibration: Time for Transformative Approach to Risk Score Validation?\*. *Journal of the American College of Cardiology* **67**, 2131–2134 (2016).
  97. Ishibashi, S. *et al.* Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. *J. Clin. Invest.* **92**, 883–93 (1993).
  98. Plump, A. S. *et al.* Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. *Cell* **71**, 343–353 (1992).
  99. Williams, H., Johnson, J. L., Carson, K. G. S. & Jackson, C. L. Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice. *Arterioscler. Thromb. Vasc. Biol.* **22**, 788–792 (2002).
  100. Libby, P. Murine ‘model’ monotheism: an iconoclast at the altar of mouse. *Circ. Res.* **117**, 921–5 (2015).
  101. Pasterkamp, G. *et al.* Human Validation of Genes Associated With a Murine Atherosclerotic Phenotype. *Arterioscler. Thromb. Vasc. Biol.* (2016). doi:10.1161/ATVBAHA.115.306958
  102. Shiomi, M. *et al.* Vasospasm of atherosclerotic coronary arteries precipitates acute ischemic myocardial damage in myocardial infarction-prone strain of the watanabe heritable hyperlipidemic rabbits. *Arterioscler. Thromb. Vasc. Biol.* **33**, 2518–2523 (2013).
  103. Burke, a P. *et al.* Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. *N. Engl. J. Med.* **336**, 1276–1282 (1997).
  104. Dai, J. *et al.* Association between cholesterol crystals and culprit lesion vulnerability in patients with acute coronary syndrome: An optical coherence tomography study.

- Atherosclerosis* **247**, 111–7 (2016).
105. Ino, Y. *et al.* Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome. *JACC Cardiovasc. Interv.* **4**, 76–82 (2011).
  106. Niccoli, G. *et al.* Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. *Eur. Heart J.* **36**, 1377–84 (2015).
  107. Refaat, H. *et al.* Optical coherence tomography features of angiographic complex and smooth lesions in acute coronary syndromes. *Int. J. Cardiovasc. Imaging* **31**, 927–34 (2015).
  108. Saia, F. *et al.* Eroded Versus Ruptured Plaques at the Culprit Site of STEMI: In Vivo Pathophysiological Features and Response to Primary PCI. *JACC. Cardiovasc. Imaging* **8**, 566–75 (2015).
  109. Jia, H. *et al.* In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. *J. Am. Coll. Cardiol.* **62**, 1748–1758 (2013).
  110. Ong, D. S. *et al.* Coronary Calcification and Plaque Vulnerability: An Optical Coherence Tomographic Study. *Circ. Cardiovasc. Imaging* **9**, (2016).
  111. Vergallo, R. *et al.* Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. *Am. Heart J.* **167**, 59–67 (2014).
  112. Wang, L. *et al.* Variable underlying morphology of culprit plaques associated with ST-elevation myocardial infarction: an optical coherence tomography analysis from the SMART trial. *Eur. Heart J. Cardiovasc. Imaging* jev105– (2015). doi:10.1093/ehjci/jev105
  113. Lee, C. W. *et al.* Differences in intravascular ultrasound and histological findings in culprit coronary plaques between ST-segment elevation myocardial infarction and stable angina. *J. Thromb. Thrombolysis* **37**, 443–449 (2014).
  114. Bogale, N. *et al.* Optical coherence tomography (OCT) evaluation of intermediate coronary lesions in patients with NSTEMI. *Cardiovasc. Revasc. Med.* **17**, 113–8 (2016).